A retrospective analysis of 728 people with type 2 diabetes on non-insulin therapies using isCGM found a 1.6 pp (16 mmol/mol) HbA1c reduction (p<0.001); a limitation of this analysis was the lack of a control group [31]. The gene discussed is INS; the disease is type 2 diabetes mellitus.